CSBIO(SZ:300255) Xin Lang Cai Jing·2025-10-20 03:02Group 1 - The core point of the news is that Changshan Pharmaceutical experienced a stock price increase of 5.13%, reaching 51.24 CNY per share, with a trading volume of 543 million CNY and a turnover rate of 1.20%, resulting in a total market capitalization of 47.093 billion CNY [1] - Changshan Pharmaceutical, established on September 28, 2000, and listed on August 19, 2011, is primarily engaged in the research, production, and sales of heparin series products, with main business revenue composition being 47.47% from water injection preparations, 39.24% from heparin raw materials, and 13.29% from other products [1] Group 2 - From the perspective of fund holdings, one fund under E Fund has a significant position in Changshan Pharmaceutical, with the E Fund Growth ETF (159572) holding 352,200 shares, accounting for 2.07% of the fund's net value, making it the largest holding [2] - The E Fund Growth ETF (159572) was established on December 15, 2023, with a latest scale of 792 million CNY, and has achieved a year-to-date return of 20.12%, ranking 2291 out of 4218 in its category, and a one-year return of 25.61%, ranking 2080 out of 3865 [2]